Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / weight management | Not covered |
Plan type: Commercial non-Medicare. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
This varies by plan. BCBSIL runs weight-loss and GLP-1 coverage through Prime Therapeutics as optional employer-group programs (GLP-1 New to Therapy, GLP-1 30-Day Max, and Anti-Obesity 30-Day Max). BCBSIL states the categories and medications included may vary according to employer group selections, so Wegovy is covered only when the employer purchased anti-obesity or GLP-1 drug coverage. Plans that did not elect it treat weight-loss drugs as a benefit exclusion, not a medical-necessity denial.
If the weight-loss exclusion above applies to you, you are paying for this yourself.
Coverage by indication
| BMI threshold | 30, or 27 with a weight-related comorbidity |
| Step therapy | Varies by plan; some plans require documentation of prior anti-obesity medications |
What the prior authorization needs:
- Coverage applies only if the employer group elected the GLP-1 or anti-obesity drug benefit through Prime Therapeutics; many plans exclude weight-loss drugs entirely.
- Prior authorization applies where the benefit is elected, administered under BCBSIL's weight management program with Prime Therapeutics.
- BMI of 30 or higher, or 27 or higher with a weight-related comorbidity, per standard weight-management criteria. BCBSIL does not publish its exact clinical criteria document.
- Documentation of a reduced-calorie diet and increased physical activity, or participation in a lifestyle or behavioral weight-management program.
- Reauthorization typically requires at least 5% weight loss from baseline.
Source: Pharmacy Benefit for GLP-1 and/or Anti-Obesity Drug Therapy. payer provider bulletin. Verified August 28, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time. Some participants get a placebo, decided at random.
What it costs without insurance
The programs below bill you directly.
Frequently asked questions
Does BCBS Illinois cover Wegovy?
Whether Blue Cross and Blue Shield of Illinois covers Wegovy for weight loss depends on the plan. BCBSIL and its pharmacy benefit manager, Prime Therapeutics, offer weight-loss and GLP-1 coverage as an optional benefit that each employer group chooses to add or leave out, so many plans exclude anti-obesity drugs entirely. Where an employer elected the benefit, Wegovy is covered with prior authorization, generally at a BMI of 30 or higher (or 27 or higher with a weight-related condition) plus documented diet and lifestyle efforts. Members should confirm with their plan or employer whether weight-loss drugs are included before assuming coverage. This reflects the published policy verified August 2026.
Why might BCBS Illinois deny Wegovy even if I meet the criteria?
BCBSIL runs weight-loss and GLP-1 coverage through Prime Therapeutics as optional employer-group programs (GLP-1 New to Therapy, GLP-1 30-Day Max, and Anti-Obesity 30-Day Max). BCBSIL states the categories and medications included may vary according to employer group selections, so Wegovy is covered only when the employer purchased anti-obesity or GLP-1 drug coverage. Plans that did not elect it treat weight-loss drugs as a benefit exclusion, not a medical-necessity denial.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
